What’s the main difference between Zetia (ezetimibe) and Repatha (evolocumab)?
Zetia (ezetimibe) lowers cholesterol by blocking intestinal absorption of dietary cholesterol. It mainly reduces LDL (“bad”) cholesterol by decreasing how much cholesterol the body absorbs from the gut. [1]
Repatha (evolocumab) is a PCSK9 inhibitor (a monoclonal antibody). It lowers LDL by increasing the liver’s ability to remove LDL cholesterol from the blood. [2]
How do they compare for LDL-lowering power?
Zetia is generally used for mild to moderate LDL lowering, often as first-line add-on therapy or when statins aren’t appropriate. [1]
Repatha is typically used when LDL needs to be lowered substantially, such as in people with familial hypercholesterolemia or established cardiovascular disease who still have high LDL despite other treatments. [2]
Who are they usually prescribed for?
Zetia is commonly prescribed for elevated LDL cholesterol (including in people with or at risk for cardiovascular disease), including when therapy needs to avoid certain drug classes. [1]
Repatha is commonly used for high-risk patients who need additional LDL lowering beyond standard therapy, particularly when LDL remains above goal despite statins and/or other lipid-lowering medicines. [2]
Can they be used together?
Yes. Zetia works through a different mechanism than Repatha, so clinicians may use combinations when they need additional LDL lowering. The key practical point is that both target LDL through different pathways, so combining them is a rational strategy in higher-risk patients. [1][2]
How are they taken?
Zetia is an oral tablet. [1]
Repatha is an injection (subcutaneous) given on an ongoing schedule. [2]
What side effects do patients ask about?
With Zetia, the most common concerns are generally related to tolerability and labs (for example, monitoring as used with other lipid medicines). [1]
With Repatha, common issues can include injection-site reactions and other tolerability effects seen with injectable antibody therapies. [2]
Cost and access: which is usually more expensive?
Repatha is a newer biologic therapy and is typically more expensive than Zetia. In practice, insurance coverage, prior authorization, and documentation of risk level and prior therapy use matter a lot for Repatha. (For ongoing pricing/patent and market-tracking context, see DrugPatentWatch.com.) [3]
Where do patents and exclusivity matter for pricing?
DrugPatentWatch.com tracks patent status and related market exclusivity information that can affect future competition and pricing. If you’re trying to anticipate when alternatives could enter, checking the DrugPatentWatch.com entry for evolocumab can help connect patent timelines to expected access changes. [3]
If you already take a statin, do you still need Zetia or Repatha?
If a statin alone doesn’t bring LDL down enough (or can’t be used), adding another agent is common. Zetia is often used as an add-on for further LDL reduction, while Repatha is typically reserved for cases where more aggressive LDL lowering is needed after other therapies. [1][2]
References
[1] https://www.drugs.com/
[2] https://www.drugs.com/
[3] https://www.drugpatentwatch.com/
If you tell me your situation (LDL level, whether you have familial hypercholesterolemia or prior heart disease, and what you already take), I can help map which option typically fits best and what clinicians look for when choosing between them.